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Background: Treatment with bleomycin–etoposide–cisplatin (BEP) impairs renal function and increases the risk of late
cardiovascular disease (CVD) and death. We investigated the inﬂuence of BEP on glomerular ﬁltration rate (GFR) and
assessed the importance of GFR changes on CVD and death in a large cohort of germ-cell cancer survivors.
Patients and methods: BEP-treated patients (N = 1206) were identiﬁed in the Danish DaTeCa database, and merged
with national registers to identify late toxicity. GFR were measured (51Cr-EDTA clearance) before and after treatment and
at 1, 3 and 5-year follow-up. The inﬂuence of BEP on GFR was evaluated with a linear mixed model. Risk factors for late
toxicity were identiﬁed by a landmark analysis adjusting for covariates. The cohort was compared with the background
population with standardized hospitalization/mortality rates.
Results: GFR changed (ΔGFR) −11.3%, −15.4% and −25.9% after three, four and ﬁve+ cycles of BEP. For patients
with impaired renal function before treatment the changes were 4.3%, 0.0% and −12.8%, respectively. During follow-up
a signiﬁcant rebound of GFR was documented. Compared with the background population, all patients, irrespective of
renal function, had an increased risk of CVD and death. This risk depended on chronic kidney disease stage before treat-
ment but not after treatment. ΔGFR had no inﬂuence on risk of late toxicity [death: hazard ratio (HR) 1.06, P = 0.50; CVD:
HR 0.97, P = 0.61].
Conclusions: Renal function after BEP is closely related to number of cycles, but the changes in GFR are partly
reversible and have no impact on risk of CVD or death.
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introduction
The majority of patients with germ-cell cancer (GCC) survive
their disease. Accordingly the prime focus has shifted from in-
creasing survival to improvement of survivorship. Cisplatin is
part of the standard treatment of GCC [bleomycin, etoposide
and cisplatin (BEP)] and renal impairment is one of the main
toxicities associated with cisplatin-based chemotherapy. The
toxicity is associated with the number of treatment cycles
and the accumulated doses of cisplatin [1]. Previous studies on
renal toxicity are based on patients treated with high doses,
older treatment regimens [2, 3], or based on estimates of renal
function (eGFR) and small cohorts with an inherent risk of
inexactness [4, 5].
Studies on the general population show a clear correlation
between renal function, as deﬁned by the National Kidney
Foundation Stages of Chronic Kidney Disease (CKD), and later
risk of developing cardiovascular disease (CVD) or death [6].
Treatment with BEP enhances the risk of CVD as a late effect
[7], but an association between renal function loss after chemo-
therapy and later CVD has not been established.
In this study, we investigate the inﬂuence of BEP on long-
term renal function using measured glomerular ﬁltration rate
(GFR), and investigate whether there is an association between
renal impairment, late toxicities like CVD and death in GCC
patients.
materials and methods
population and treatment characteristics
Subjects eligible for inclusion (N = 1206) were identiﬁed in the retrospective
DaTeCa database covering Danish GCC patients diagnosed 1984–2007
(for full description, see supplementary Appendix, available at Annals of
Oncology online). Inclusion criteria were: patients with disseminated GCC
(gonadal, extragonadal or relapse after stage I disease) treated with BEP
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(three cycles or more) in standard doses [bleomycin 15 000 IU/m2/day i.v.
day 1, 8, 15, etoposide (VP-16) 100 mg/m2/day day1–5 and cisplatin
(CDDP) 20 mg/m2/day day 1–5 every 3 weeks] or double-dose cisplatin.
Initially four cycles was standard treatment. However, since 2001, three
cycles has been offered in the good prognostic group. All patients included
had measurements of GFR before chemotherapy.
Exclusion criteria: Other primary treatment than BEP, treatment failure
or death due to GCC, total N = 275.
To analyze the inﬂuence of cumulative cisplatin dose, the patients were
divided by number of cycles received: three cycles (300 mg/m2 cisplatin),
four cycles (400 mg/m2) and ﬁve cycles or more or double-dose cisplatin
(500 mg/m2 or more). Hydration remained uniform over time with 2-l iso-
tonic saline before cisplatin and additional 1–2 l after. Diuretics were only
administered in special cases, and no magnesium was added to hydration.
There was no predeﬁned cutoff of renal function, where patients would not
receive cisplatin-based triplets. Patients with residual tumor after chemother-
apy had secondary surgery. In later years, patients with seminoma were
followed with positron emission tomography (PET) and computed tomog-
raphy scans and only PET-positive tumors were resected.
outcome measures
Renal function, weight, height and clinical examinations were assessed
before chemotherapy, after chemotherapy and during follow-up at 1, 3 and 5
years after completion of treatment. Measurements before chemotherapy
were done 1–5 days ahead of treatment, and after chemotherapy the mea-
surements were carried out less than a week after treatment cessation.
During follow-up, all assessments were made in conjunction with outpatient
visits. The number of patients with a complete dataset of GFR-measure-
ments was 275. Missing renal measurements were caused by local guidelines
not stating that the measurements should be done (N = 877), or censuring of
patients before 5 years follow-up (N = 53).
GFR was measured by the one sample 51Cr-ethylenediaminetetra acetic
acid clearance technique using two (for duplicate determination) plasma
samples 200 min after tracer injection [8], and normalized to a body surface
area of 1.73 m2. CKD was deﬁned according to National Kidney Foundation
guidelines into stage I (GFR above 90 ml/min/1.73 m2), stage II (GFR 60–89
ml/min/1.73 m2), stage III (GFR 30–59 ml/min/1.73 m2), stage IV (GFR 15–
29 ml/min/1.73 m2) and stage V (GFR below 15 ml/min/1.73 m2) [9].
assessment of late toxicity
In Denmark, all citizens are assigned with a unique personal identiﬁcation
number. This number is recorded in the Danish Civil Registration System
(CRS) [10]. By linkage to the CRS, we gained information on emigration and
immigration, disappearance and death.
Data on CVD and late renal disease was obtained from the National
Patient Registry, which houses data on hospital discharge from 1977– and
outpatient visits since 1995, including date and diagnosis [11]. Diagnoses
were coded according to ‘International Classiﬁcation of Diseases, 8th revi-
sion’ (ICD-8) until 1991; thereafter the ‘10th revision’ (ICD-10) was used.
Information about cause of death was obtained through linkage to the
Danish Register of Causes of Death [12].
Major cardiovascular events were deﬁned at ﬁrst appearance of coronary
heart disease, cerebrovascular accident or heart failure in any register, either
as a cause of admission or cause of death. Patients with a disease event
before orchiectomy were censored. In order to compare the present cohort
with the Danish background population we gathered data from Statbank.dk
(Statistics Denmark), which houses information on all diagnoses from 1991–
and deaths from 1984– in Denmark. Full information on deﬁnitions of
disease is available in (supplementary Table S1, available at Annals of
Oncology online).
statistics
Descriptive statistics are presented by medians and quartiles for quantitative
data. GFR were analyzed on the log scale using mixed modeling with
repeated measures. The explanatory variables considered were: time after
initial treatment, BEP treatment, age, CKD before treatment and surgery.
Results are presented back transformed with 95% conﬁdence intervals (CIs).
The inﬂuence of renal function on late effects was analyzed with a land-
mark analysis on time points pre and post-chemotherapy to evaluate the im-
portance of renal function changes caused by BEP. Cox proportional hazard
model was used, and the hazard assumption was graphically assessed using
log–log plots. The following covariates were included: age at treatment,
smoking habits (dichotomized as ever versus never), treatment period, post-
chemotherapy surgery and number of treatment cycles. As smoking habits
had missing values (Table 1), a multiple imputation method (20 imputa-
tions) based on covariates, outcome and date of treatment was used [13].
Inclusion of BMI as covariate was omitted due to a high number of missing
values. The missing values were regarded as missing at random. GFR was
evaluated as a continuous covariate and stratiﬁed according to CKD stages.
Tests for interactions were carried out where applicable.
Standardized hospitalization rates (SHRs) and standardized mortality
rates (SMRs) were calculated as observed number divided by expected
number of cases based on the hospitalization/mortality rate in Denmark.
Patients were censored at time of metachronous GCC (N = 9), emigration
(N = 28), death (N = 69), disappearance from Danish Civil Registry (N = 1)
or 30 November 2012, whichever occurred ﬁrst.
A z-test of proportions was used to test for signiﬁcant differences over
time in demographics and treatment characteristics. P values <5% were con-
sidered signiﬁcant. Statistical calculations were done using SAS (v9.3, SAS
Institute, Cary, NC) and SPSS 20.0 (SPSS, Chicago, IL).
results
patient characteristics
Characteristics are listed in Table 1. A total of 1206 patients
were eligible for analysis. The median age and follow-up of the
total population was 31.6 [interquartile range (IQR): 25.9–39.1]
and 15.2 (IQR: 9.3–21.5) years, respectively. Characteristics were
consistent over time concerning disease primary, age distribu-
tion, post-chemotherapy surgery, prognostic group and CKD
stage before treatment, but signiﬁcant changes were noted in the
remaining characteristics. In total, 387 (32.1%) patients under-
went surgery for residual tumor, 2 (0.6%) of these had nephrec-
tomy during surgery. Patients who were excluded due to death
of GCC or treatment failure after BEP did not differ signiﬁcantly
in changes of renal function, but were signiﬁcantly older than
patients included in analysis (supplementary Table S2, available
at Annals of Oncology online).
renal function
Numbers of patients with GFR measurements were 1206, 1112,
557, 353 and 322 pretreatment, post-treatment and 1, 3 and 5
years after treatment, respectively. Overall median GFR before
treatment was 109 ml/min/1.73 m2 (IQR: 99–121). Out of these,
126 patients belonged (10.5%) to CKD stage II, and 16 patients
(1.3%) was in stage III. After treatment median GFR was 94 ml/
min/1.73 m2 (IQR: 83–105), 406 (36.5%) in CKD stage II and
42 (3.8%) in stage III.
Based on the mixed model, several covariates had signiﬁcant
inﬂuence on the changes of GFR (ΔGFR): number of treatment
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cycles, CKD stage before treatment, and a signiﬁcant interaction
between treatment and CKD stage. Age at treatment and sec-
ondary surgery had no inﬂuence on ΔGFR. Treatment with BEP
signiﬁcantly reduced renal function according to number of
chemotherapy cycles (Figure 1).
For patients with normal renal function before treatment,
GFR post-treatment changed −11.3% after three cycles, after
four cycles −15.4% and after ﬁve cycles or more −25.9%. In
patients with decreased renal function before treatment (CKD
stage II or III), GFR after three cycles changed 4.3%, four cycles
0.0% and ﬁve cycles or more −12.8%.
During follow-up, there was a signiﬁcant rebound in all treat-
ment groups; however, the renal function remained subnormal
in patients in CKD stage I before treatment, even when adjusting
for the physiological decline in renal function in the normal
population.
Table 1. Patient characteristics at time of treatment
Year of BEP treatment 1984–1989 1990–1999 2000–2007 Total
No. of patients included 271 521 414 1206
Primary (%)
St I (relapse) 79 (29.2) 163 (31.3) 145 (35.0) 385 (34.1)
Disseminated, gonadal 173 (63.8) 325 (62.4) 235 (56.8) 681 (60.3)
Extragonadal retroperitoneal 16 (5.9) 26 (5.0) 29 (7.0) 54 (4.8)
Extragonadal mediastinal 3 (1.1) 7 (1.3) 5 (1.2) 10 (0.9)
Age at treatment, years (%)
15–24 67 (24.7) 114 (21.9) 77 (18.6) 258 (21.4)
25–34 116 (42.8) 223 (42.8) 156 (37.7) 495 (41.0)
35–44 60 (22.1) 115 (22.1) 102 (24.6) 277 (23.0)
45–54 17 (6.3) 50 (9.6) 54 (13.0) 121 (10.0)
55- 11 (4.1) 19 (3.6) 25 (6.0) 55 (4.6)
BMI (%)
Underweight (–18.5) 6 (2.2) 3 (0.6) 3 (0.7) 12 (1.0)
Normal (18.5–25.0) 67 (24.7) 103 (19.8) 83 (20.0) 253 (21.0)
Overweight (25.0–30.0) 29 (10.7) 41 (7.9) 62 (15.0) 132 (10.9)
Obese (30.0–) 5 (1.8) 13 (2.5) 24 (5.8) 42 (3.5)
N/A 164 (60.5) 361 (69.3) 242 (58.5) 767 (63.6)
Smoking habits (%)
Never 55 (20.3) 101 (19.4) 109 (26.3) 265 (22.0)
<10 g/day 14 (5.2) 14 (2.7) 18 (4.3) 46 (3.8)
10–19 g/day 36 (13.3) 52 (10.0) 35 (8.5) 123 (10.2)
20– g/day 28 (10.3) 60 (11.5) 38 (9.2) 126 (10.4)
Smoker, unknown number 1 (0.4) 4 (0.8) 4 (1.0) 9 (0.7)
Former smoker 1 (0.4) 8 (1.5) 8 (1.9) 17 (1.4)
N/A 136 (50.2) 282 (54.1) 202 (48.8) 620 (51.4)
Histology (%)
Seminoma 39 (14.4) 130 (25.0) 116 (28.0) 285 (23.6)
Nonseminoma 232 (85.6) 391 (75.0) 298 (72.0) 921 (76.4)
Surgery residual tumor (%)
Yes 98 (36.2) 145 (27.8) 144 (34.8) 387 (32.1)
No 173 (63.8) 376 (72.2) 270 (65.2) 819 (67.9)
IGCCCG prognostic group (%)
Good 203 (76.3) 394 (77.0) 322 (80.7) 919 (78.1)
Intermediate 45 (16.9) 89 (17.4) 53 (13.3) 187 (15.9)
Poor 18 (6.8) 29 (5.7) 24 (6.0) 71 (6.0)
CKD stage before treatment (%)
I 238 (87.8) 466 (89.4) 360 (87.0) 1064 (88.2)
II 29 (10.7) 48 (9.2) 49 (11.8) 126 (10.4)
III 4 (1.5) 7 (1.3) 5 (1.2) 16 (1.3)
Treatment cycles (%)
3 3 (1.1) 36 (6.9) 278 (67.1) 317 (26.3)
4 193 (71.2) 442 (84.8) 122 (29.5) 757 (62.8)
5–/high dose 75 (27.7) 43 (8.3) 14 (3.4) 132 (10.9)
N/A, not available; CKD, chronic kidney disease.
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renal function, CVD and death
Late effects are listed in Table 2. The risk of a major cardiovascu-
lar event after 20 years was 12.7%. CKD stage III before treat-
ment was associated with a nonsigniﬁcantly increased risk of
later death [hazard ratio: 2.25 (0.79–6.41)], and after treatment
the association was further diluted by nonsigniﬁcant associa-
tions with CVD and death (Table 3). Correspondingly ΔGFR
was not associated with risks of CVD or death, neither post-
treatment nor at 5 years of follow-up. The only signiﬁcant cov-
ariates for later death in all models, were age and smoking.
CKD stage after treatment and number of chemotherapy
cycles were compared with the background population with
respect to the risk of major CVD or death, Table 3. In total, 93
patients died during follow-up versus an expected number of 46
[SMR: 2.03 (1.64–2.48)]. Cause of death was secondary cancer
(N = 28), CVD (N = 20), and other (N = 45), (supplementary
Table S3, available at Annals of Oncology online). The SHR for
CVD in the whole cohort was signiﬁcantly increased to 1.38
(1.22–1.55), but with no correlation to treatment intensity or
CKD-stage.
discussion
The present study includes the most comprehensive data con-
cerning the inﬂuence of BEP treatment on renal function. All
patients included were only treated with standard ﬁrst-line treat-
ment. The decrease in renal function was −11.3%, −15.4% and
−25.9% after three, four or ﬁve cycles or more.
As shown in previous studies [1, 4, 5, 14], the decrease in
renal function immediately after termination of chemotherapy
is highly inﬂuenced by the cumulative dose of cisplatin, but, in
contrast to these studies, we have documented a signiﬁcant re-
versibility of renal function loss during follow-up. Besides, we
found, that patients with impaired renal function before treat-
ment, quite safely can receive three to four cycles of BEP with
virtually no changes in GFR. In the majority of these patients,
the prechemotherapy renal impairment is presumably due to
mechanical obstruction from the malignant disease. Secondary
surgery did not increase the risk of renal toxicity during follow-
up, as only two patients needed nephrectomy. This ﬁnding is in
line with Stephenson et al. who also found that only a small
subset of patients undergoing postchemotherapy surgery need
nephrectomy [15].
70%
75%
80%
85%
90%
95%
100%
105%
110%
115%
Before BEP After BEP 1 Year 3 Years 5 Years
A Normal Renal Function Before BEP
70%
75%
80%
85%
90%
95%
100%
105%
110%
115%
Before BEP After BEP 1 Year 3 Years 5 Years
B Impaired Renal Function Before BEP
BEP x 3 BEP x 4 BEP x 5 or more
Figure 1. Glomerular ﬁltration rates (GFR) based on linear mixed models.
The relative GFR measured by 51Cr-EDTA clearance according to various
time points. Covariates included in the model without signiﬁcance: postche-
motherapy surgery P = 0.11, Age at treatment P = 0.62. (A) Patients with
normal renal function before treatment [chronic kidney disease (CKD) stage
I or >90 ml/min/1.73 m2]. (B) Patients with impaired renal function before
treatment (CKD stage II–III or 30–90 ml/min/1.73 m2).
Table 2. Number of patients with any late effect or death and 20 years cumulative incidence (%) according to CKD stage after treatment
Number of patients CKD-stage Total
I II III
664 406 42 1,112
Cardiovascular disease
Myocardial infarction (%) 19 (3.6) 22 (7.2) 3 (10.0) 45 (4.9)
Angina (%) 41 (8.6) 27 (9.5) 3 (7.3) 71 (8.6)
Cerebrovascular accident (%) 11 (2.0) 15 (4.8) 7 (21.4) 33 (3.7)
Heart failure (%) 9 (1.6) 9 (2.4) 0 (0.0) 18 (1.7)
Any above 57 (11.0) 42 (14.9) 9 (27.2) 108 (12.7)
Chronic kidney disease (%) 4 (0.7) 6 (2.2) 4 (10.8) 14 (1.6)
Death (%) 35 (6.6) 42 (11.2) 8 (18.4) 93 (9.1)
Some patients have more than one cardiovascular disease. Chronic kidney disease is deﬁned as appearance of chronic kidney disease in a central
registry.
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In the present study, we found an overall signiﬁcantly in-
creased risk of major CVD and death compared with the back-
ground population. These ﬁndings are in accordance with other
large studies [7, 16]. A decreased pretreatment renal function
was associated with a nonsigniﬁcantly increased risk of CVD, in
line with large population-based studies [6, 17]. We could,
however, not detect a relationship with changes in renal func-
tion during treatment and CVD despite a long median follow-
up of 15 years. There are several possible explanations for the
missing impact of these changes.
First, the decrease in GFR was small and therefore likely clin-
ically insigniﬁcant. In the present study, one-third ended in
CKD stage II and only 3% in stage III after treatment. In recent
smaller studies based on eGFR, 10–23% of patients ended in
CKD stage III during follow-up [4, 5, 18]. First-line treatments
included a wide range of chemotherapy regimens and addition-
ally a large part of patients received salvage or second-line
chemotherapy (26–43%). Conversely, in a small study by Fossa
et al. using mGFR, patients treated with conventional dose BEP
only, experienced a long-term decline in GFR of only 10% [1],
which is in line with the present results. Secondly, patients with
the highest pretreatment GFR also had the highest relative
change in GFR, and, consequently, these patients still have a
sufﬁcient renal function. Possibly, renal function loss in other-
wise healthy adults may be of minor importance. In a study on
kidney donors, no increased risk of CVD is seen in the ﬁrst
decade after kidney donation [19]. Additionally, during follow-
up GFR normalize in a large proportion of our cohort. A recent
study employing eGFR [18] describe a continuous decrease of
renal function after treatment has ceased. This is likely caused
by imprecision of the estimates used [20].
It seems that, even a few cycles of BEP increases the risk of
CVD and we could not detect a signiﬁcant difference with three
or four cycles of cisplatin and later risk of CVD or death. The
body of patients receiving small or large cumulative doses of cis-
platin was relatively modest due to exclusion of patients with
relapse and second-/third-line treatment and the nonuse of one
or two cycles of adjuvant BEP in patients with stage I nonsemi-
noma. Also we did not include patients who did not receive
BEP. However, patients on surveillance have normal renal func-
tion during follow-up and do not experience an increased risk
of CVD [1, 7, 16].
We have looked at a large, unselected cohort of GCC-patients
with a long follow-up. Due to the time-span and retrospective
nature of the cohort, some limitations must be considered.
There were missing values in important confounders, leading to
the use of imputational methods. If the confounders were
omitted from analyses (results not shown), no changes in the
results were noted, strengthening the interpretation of the
results. Treatment and registration habits in the national regis-
ters changed slightly over time. Three cycles of chemotherapy to
the good prognosis group were introduced in 2001 implying
short median follow-up for patients with only three cycles of
BEP and the evaluation of late effects for this group might be
too early. A missing association of renal impairment and CVD
can be caused by a type II error, if the cohort has been too small
to show. However, we did ﬁnd a signiﬁcantly increased risk of
CVD and death in patients treated with chemotherapy, and the
Table 3. Hazard rates adjusted for age, time, smoking habits and postchemotherapy resection at different time points
Outcome Before treatment After treatment SHR/SMR
Covariate P HR (95%CI) P HR (95% CI)
Death CKD stage
I 1 1 1.93 (1.51–2.45)
II 0.17 1.52 (0.84–2.73) 0.80 0.93 (0.55–1.60) 2.17 (1.30–3.38)
III 0.09 2.40 (0.87–6.57) 0.35 1.61 (0.60–4.29) 3.43 (1.11–8.02)
No. of cycles
3 1 1 1.08 (0.40–2.36)
4 0.75 0.85 (0.31–2.32) 0.68 0.79 (0.26–2.43) 2.07 (1.61–2.62)
5–/high dose 0.95 1.04 (0.31–3.46) 0.91 0.93 (0.24–3.51) 2.54 (1.53–3.97)
Total 2.03 (1.64–2.48)
CVD CKD stage
I 1 1 1.40 (1.23–1.60)
II 0.36 1.31 (0.40–1.67) 0.53 0.86 (0.55–1.38) 1.12 (0.80–1.52)
III 0.13 2.29 (0.80–6.60) 0.30 1.65 (0.63–4.32) 2.31 (1.23–3.96)
No. of cycles
3 1 1 1.56 (1.07–2.19)
4 0.57 0.81 (0.40–1.66) 0.81 0.91 (0.41–2.00) 1.40 (1.21–1.61)
5–/high dose 0.15 0.43 (0.14–1.37) 0.28 0.52 (0.16–1.72) 1.17 (0.82–1.61)
Total 1.38 (1.22–1.55)
The inﬂuence of ΔGFR (GFR post-treatment –GFR pretreatment, change of 10 ml/min/1.73 m2) in the same models: Death [P = 0.50, HR: 1.06 (0.90–
1.25)] and CVD [P = 0.61, HR: 0.97 (0.84–1.11)]. At 5-year follow-up, the inﬂuence of ΔGFR (GFR at 5 years –GFR pretreatment) was: Death
[P = 0.19, HR: 0.83 (0.62–1.11)] and CVD [P = 0.45, HR: 0.89 (0.66–1.20)].
HR, hazard ratio; CKD stage, chronic kidney disease stage; CVD, cardiovascular disease; CI, conﬁdence interval; SHR, standardized hospitalization rate;
SMR, standardized mortality rate.
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results did not in any way favor a trend towards an association
between renal function loss and risk of late effects.
Cisplatin-based combination chemotherapy induces signiﬁcant
deteriorations in renal function. These changes are not associated
with an increased risk of late CVD or death. However, we
conﬁrm that treatment with chemotherapy in itself causes a risk,
and that patients with impaired renal function before treatment
have an additionally increased risk. The latter patient group needs
close follow-up concerning cardiovascular risk factors.
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